You may not spend much time thinking about contract manufacturing organizations in your daily life, but they quietly influence global healthcare behind the scenes. In recent years, these specialized partners proved essential in manufacturing hundreds of millions of vaccine doses, saving countless lives while stabilizing fragile pharmaceutical supply chains during unprecedented global health crises.
Contract manufacturing organizations collaborate closely with biotech pioneers and major pharmaceutical enterprises to scale up research, development, and mass production. Beyond bulk drug substance manufacturing, they frequently provide critical support services like biosafety testing, aseptic fill and finish, and specialized packaging for complex therapies. If you want to dig deeper, our guide on How to Choose the Right Lawyer for Your Legal Needs covers this well.
At the absolute forefront of this vital industry stands Samsung Biologics, a leading global CDMO that continues to make massive waves. As the medical sector evolves, the company is securing its position through aggressive global expansion, strategic acquisitions, and massive manufacturing footprints designed to handle next-generation treatments.
Samsung Biologics: Recent Performance & News
Want to get fully caught up on what Samsung Biologics has been achieving lately? The company has captured massive industry attention by securing approximately USD 13 billion in long-term manufacturing contracts with 16 of the world’s 20 largest pharmaceutical corporations, proving its immense market reliability.
Partnerships with global industry leaders remain a cornerstone of their ongoing business strategy. Samsung Biologics continues to exhibit at premier industry gatherings like the BIO International Convention, showcasing its end-to-end biopharma services to clients worldwide while establishing a formidable footprint across multiple continents.
Expanding Capabilities for mRNA Vaccine Manufacturing and Beyond
Samsung Biologics is constantly upgrading its facilities to handle specialized drug substances, including dedicated suites for mRNA vaccine production and advanced biological therapies. This agility allows them to serve clients developing diverse mRNA treatments on a much larger commercial scale than was possible just a few years ago.
Looking ahead to early 2027, the company is actively preparing to offer specialized drug product services for antibody-drug conjugates, commonly known as ADCs. By continuously broadening their technical portfolio, they ensure that biotech clients can seamlessly transition from early-stage clinical development all the way to commercialization under one roof.
Development of Record-Breaking Manufacturing Plant and US Expansion
The company has also shattered traditional industry benchmarks by developing massive single-site manufacturing capacity that far surpasses older facilities. A primary focus in these plants is the modernization of automation processes, which delivers superior efficiency, strict quality control, and better service for global pharma partners.
In a major milestone marking its first manufacturing presence inside the United States, Samsung Biologics completed the acquisition of a facility in Rockville, Maryland. This strategic addition successfully raised the company’s total global manufacturing capacity to 845,000 liters, positioning them closer to major North American clients. For more on this, our article on Understanding the New MOHRE Law in the UAE (2025) is a good next read.
What’s Next for Samsung Biologics in their Role as a Contract Manufacturing Organization?
In July 2026, Samsung Biologics announced another landmark move by acquiring Swiss peptide contract development and manufacturing organization PolyPeptide Group. This bold move significantly broadens their specialized chemical and peptide synthesis capabilities on a truly international scale.
As leadership looks beyond the current decade, the organization remains focused on evolving as a top-tier biopharmaceutical partner through continuous capital investment and footprint expansion. Driven by a mission to improve global health accessibility, Samsung Biologics continues to redefine what modern biomanufacturing can achieve for patients worldwide.
FAQs
What services does Samsung Biologics provide as a CDMO?
Samsung Biologics offers comprehensive end-to-end biologics services, including cell line development, clinical and commercial CGMP manufacturing, biosafety testing, and aseptic fill and finish packaging.
What major acquisition did Samsung Biologics make in 2026?
In July 2026, the company announced its agreement to acquire Swiss peptide contract development and manufacturing organization PolyPeptide Group to expand its specialized peptide capabilities.
Where is Samsung Biologics’ manufacturing capacity located?
While its massive primary manufacturing campus is located in Incheon, South Korea, the company expanded into the United States by acquiring a facility in Rockville, Maryland, bringing total global capacity to 845,000 liters.
What new services are planned for the near future?
Samsung Biologics is strategically expanding its service portfolio to offer specialized drug product services for antibody-drug conjugates starting in early 2027.
How many major pharmaceutical clients does Samsung Biologics work with?
The company has secured roughly USD 13 billion in long-term manufacturing contracts, working alongside 16 of the top 20 largest pharmaceutical companies in the world.